Katharina Luise Hupa-Breier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katharina Luise Hupa-Breier has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Heiner Wedemeyer
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
5 shared publications Elmar Jaeckel
4 shared publicationsHeiner Wedemeyer
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology Hannover Medical School Hannover Germany
4 shared publications- Matthias Hardtke-Wolenski
Dept. of Gastroenterology Hepatology, Infectious Disease and Endocrinology Hannover Medical School Hannover Germany
3 shared publications Richard Taubert
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
3 shared publications- Richard Taubert
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology Hannover Medical School Hannover Germany
3 shared publications
Latest Publications
- Open Access
- 20 February 2026
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 50 (4) , 544-556
Association between specialized nutrition support and 90‐day mortality relative to standard of care in malnourished adults with decompensated cirrhosis: A retrospective cohort study
Background: Malnutrition is common among patients with decompensated liver cirrhosis and linked to poor prognosis. Guidelines recommend intensified nutrition support e.g. parenteral nutrition, but evidence regarding safety and effectiveness is scarce. We aimed to investigate the impact of nutrition support, specifically parenteral nutrition, on mortality (primary end point) and on cirrhosis‐specific complications (secondary end points) in patients with advanced liver cirrhosis. Methods: Consecutive malnourished patients with decompensated cirrhosis treated at our center between 2013 and 2018 were investigated. Fifty‐three patients received specialized nutrition support; 33 received parenteral nutrition. The specialized nutrition support group (cohort 1) and the home parenteral nutrition group (cohort 2) were compared with patients without specific dietary support (standard‐of‐care group) after 1:1 and 1:2 propensity score matching, respectively. Mortality, hepatic encephalopathy, infections, and rehospitalization were investigated within 90 days. Results: Median baseline Model for End‐Stage Liver Disease score (possible range 6–40 points) was 18 in cohort 1 and 16 in cohort 2. No impact of specialized nutrition support on the clinical outcome was detected. Between cohort 2 and standard of care, no differences in mortality and rehospitalization were observed. Whereas parenteral nutrition was associated with increased risk for bloodstream infections (hazard ratio [HR] = 21.3; P = 0.004), overall incidence of bacterial infections was comparable between groups (HR = 0.82; P = 0.45). Of note, the likelihood for hepatic encephalopathy was significantly reduced in cohort 2 in the multivariable competing risk model (HR = 0.28; P = 0.03). Conclusion: Home parenteral nutrition seems safe overall and may ameliorate the risk for hepatic encephalopathy in candidates for liver transplant.
- 20 February 2026
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 50 (4) , 544-556
Open AccessAssociation between specialized nutrition support and 90‐day mortality relative to standard of care in malnourished adults with decompensated cirrhosis: A retrospective cohort study
Background: Malnutrition is common among patients with decompensated liver cirrhosis and linked to poor prognosis. Guidelines recommend intensified nutrition support e.g. parenteral nutrition, but evidence regarding safety and effectiveness is scarce. We aimed to investigate the impact of nutrition support, specifically parenteral nutrition, on mortality (primary end point) and on cirrhosis‐specific complications (secondary end points) in patients with advanced liver cirrhosis. Methods: Consecutive malnourished patients with decompensated cirrhosis treated at our center between 2013 and 2018 were investigated. Fifty‐three patients received specialized nutrition support; 33 received parenteral nutrition. The specialized nutrition support group (cohort 1) and the home parenteral nutrition group (cohort 2) were compared with patients without specific dietary support (standard‐of‐care group) after 1:1 and 1:2 propensity score matching, respectively. Mortality, hepatic encephalopathy, infections, and rehospitalization were investigated within 90 days. Results: Median baseline Model for End‐Stage Liver Disease score (possible range 6–40 points) was 18 in cohort 1 and 16 in cohort 2. No impact of specialized nutrition support on the clinical outcome was detected. Between cohort 2 and standard of care, no differences in mortality and rehospitalization were observed. Whereas parenteral nutrition was associated with increased risk for bloodstream infections (hazard ratio [HR] = 21.3; P = 0.004), overall incidence of bacterial infections was comparable between groups (HR = 0.82; P = 0.45). Of note, the likelihood for hepatic encephalopathy was significantly reduced in cohort 2 in the multivariable competing risk model (HR = 0.28; P = 0.03). Conclusion: Home parenteral nutrition seems safe overall and may ameliorate the risk for hepatic encephalopathy in candidates for liver transplant.
- Open Access
- 9 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (12)
From model to man: Understanding Tregs' dual role in MASLD
- 9 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (12)
Open AccessFrom model to man: Understanding Tregs' dual role in MASLD
- Open Access
- 22 January 2025
- Published by Elsevier in Molecular Metabolism
- Vol. 93, 102104
Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity
- 22 January 2025
- Published by Elsevier in Molecular Metabolism
- Vol. 93, 102104
Open AccessNovel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity
- Open Access
- 22 November 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (11) , e70039
Overweight Impacts Histological Disease Activity of De Novo Metabolic Dysfunction‐Associated Steatotic Liver Disease After Liver Transplantation
Background and Aims: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a leading indication for liver transplantation (LT), but also occurs after LT. The prevalence of de novo MASLD (dnMASLD) after LT, based on both surveillance (svLbx) and indication biopsies (indLbx), is unknown. Furthermore, the impact of the distinct cardiometabolic risk factors on histological disease activity has not been assessed. We aimed to evaluate the prevalence of dnMASLD and the association between the cardiometabolic risk factors and histological disease activity.Methods: We performed a retrospective single‐center study in a LT cohort with indLbx and svLbx. Patients with NAFLD before LT were excluded.Results: We analyzed 249 patients who underwent either svLbx or indLbx. Forty‐eight (19.2%) had either dnMASLD (n = 26/249, 10.4%) or metabolic dysfunction associated steatohepatitis (dnMASH) (n = 22/249, 8.8%). Although dnMASLD/dnMASH was more frequent in indLbx (35.1%, p < 0.01), still 16.5% of patients with svLbx had dnMASLD/dnMASH. While overweight (p < 0.01) and diabetes (p = 0.01) were more frequent in patients with dnMASH, only overweight was associated with histological disease activity in the multivariate analysis. No impact of dnMASLD on the overall survival was observed.Conclusion: While dnMASLD is more frequent in patients with indLBX, it also occurs in 16.5% of patients without signs of graft dysfunction. Overweight has the strongest impact on histological disease activity and should be monitored carefully after LT.
- 22 November 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (11) , e70039
Open AccessOverweight Impacts Histological Disease Activity of De Novo Metabolic Dysfunction‐Associated Steatotic Liver Disease After Liver Transplantation
Background and Aims: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a leading indication for liver transplantation (LT), but also occurs after LT. The prevalence of de novo MASLD (dnMASLD) after LT, based on both surveillance (svLbx) and indication biopsies (indLbx), is unknown. Furthermore, the impact of the distinct cardiometabolic risk factors on histological disease activity has not been assessed. We aimed to evaluate the prevalence of dnMASLD and the association between the cardiometabolic risk factors and histological disease activity.Methods: We performed a retrospective single‐center study in a LT cohort with indLbx and svLbx. Patients with NAFLD before LT were excluded.Results: We analyzed 249 patients who underwent either svLbx or indLbx. Forty‐eight (19.2%) had either dnMASLD (n = 26/249, 10.4%) or metabolic dysfunction associated steatohepatitis (dnMASH) (n = 22/249, 8.8%). Although dnMASLD/dnMASH was more frequent in indLbx (35.1%, p < 0.01), still 16.5% of patients with svLbx had dnMASLD/dnMASH. While overweight (p < 0.01) and diabetes (p = 0.01) were more frequent in patients with dnMASH, only overweight was associated with histological disease activity in the multivariate analysis. No impact of dnMASLD on the overall survival was observed.Conclusion: While dnMASLD is more frequent in patients with indLBX, it also occurs in 16.5% of patients without signs of graft dysfunction. Overweight has the strongest impact on histological disease activity and should be monitored carefully after LT.
- Open Access
- 12 June 2024
- Published by Elsevier in Clinical Nutrition
- Vol. 43 (8) , 1719-1727
Folic acid supplementation is associated with a decreased mortality and reduced hospital readmission in patients with decompensated alcohol-related liver cirrhosis
- 12 June 2024
- Published by Elsevier in Clinical Nutrition
- Vol. 43 (8) , 1719-1727
Open AccessFolic acid supplementation is associated with a decreased mortality and reduced hospital readmission in patients with decompensated alcohol-related liver cirrhosis
- Open Access
- 21 February 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (3) , e1592
Elevated Plasma CXCL8 Concentrations in Significant Fibrosis but Not in Subclinical Rejection After Adult Liver Transplantation
Background.: The noninvasive detection of subclinical graft injury including subclinical T cell–mediated rejection (subTCMR) is one of the unresolved challenges after liver transplantation. Recently, serum C-X-C motif chemokine ligand 8 (CXCL8) was proposed as a highly accurate marker of subTCMR in pediatric liver transplant recipients. We aimed to evaluate the accuracy of the quantification of this chemokine for predicting subTCMR in adult liver transplant recipients, as well as its capacity to classify patients who could benefit from immunosuppression reduction. Methods.: Plasma CXCL8 concentrations were measured retrospectively in a prospectively collected cohort of adult liver transplant recipients with well-characterized histologic phenotypes. Results.: In total, 78 patients were included. Median plasma CXCL8 concentrations did not differ (P = 0.24) between patients without histological evidence of rejection (3.6 [0.4–22.0] pg/mL), subTCMR (11.5 [0.4–41.0] pg/mL), clinical TCMR (9.4 [0.4–40.5] pg/mL), and other etiologies of graft injury (8.7 [0.4–31.2] pg/mL). Likewise, plasma CXCL8 concentrations did not discriminate between patients within and outside histologic criteria for immunosuppression reduction that were proposed by the 2016 Banff Working Group on Liver Allograft Pathology (cutoff: 10.9 pg/mL, sensitivity: 0.48, and specificity: 0.79). Furthermore, weak correlation was found between plasma CXCL8 and alanine aminotransferase and aspartate aminotransferase (Spearman ρ = 0.18 and 0.25). Patients with significant fibrosis (17.8 [0.4–40.5] pg/mL) showed higher plasma CXCL8 concentrations than patients without fibrosis (8.2 [0.4–41.0] pg/mL; P = 0.05). Conclusions.: Plasma CXCL8 concentrations are not predictive of subclinical graft injury or of histological criteria for the minimization of immunosuppression in adult liver transplant recipients.
- 21 February 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (3) , e1592
Open AccessElevated Plasma CXCL8 Concentrations in Significant Fibrosis but Not in Subclinical Rejection After Adult Liver Transplantation
Background.: The noninvasive detection of subclinical graft injury including subclinical T cell–mediated rejection (subTCMR) is one of the unresolved challenges after liver transplantation. Recently, serum C-X-C motif chemokine ligand 8 (CXCL8) was proposed as a highly accurate marker of subTCMR in pediatric liver transplant recipients. We aimed to evaluate the accuracy of the quantification of this chemokine for predicting subTCMR in adult liver transplant recipients, as well as its capacity to classify patients who could benefit from immunosuppression reduction. Methods.: Plasma CXCL8 concentrations were measured retrospectively in a prospectively collected cohort of adult liver transplant recipients with well-characterized histologic phenotypes. Results.: In total, 78 patients were included. Median plasma CXCL8 concentrations did not differ (P = 0.24) between patients without histological evidence of rejection (3.6 [0.4–22.0] pg/mL), subTCMR (11.5 [0.4–41.0] pg/mL), clinical TCMR (9.4 [0.4–40.5] pg/mL), and other etiologies of graft injury (8.7 [0.4–31.2] pg/mL). Likewise, plasma CXCL8 concentrations did not discriminate between patients within and outside histologic criteria for immunosuppression reduction that were proposed by the 2016 Banff Working Group on Liver Allograft Pathology (cutoff: 10.9 pg/mL, sensitivity: 0.48, and specificity: 0.79). Furthermore, weak correlation was found between plasma CXCL8 and alanine aminotransferase and aspartate aminotransferase (Spearman ρ = 0.18 and 0.25). Patients with significant fibrosis (17.8 [0.4–40.5] pg/mL) showed higher plasma CXCL8 concentrations than patients without fibrosis (8.2 [0.4–41.0] pg/mL; P = 0.05). Conclusions.: Plasma CXCL8 concentrations are not predictive of subclinical graft injury or of histological criteria for the minimization of immunosuppression in adult liver transplant recipients.
- Open Access
- 3 October 2023
- Published by Springer Nature in Hepatology International
- Vol. 17 (6) , 1359-1367
Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection
Background and aims: Hepatitis D virus (HDV) infection causes the most severe form of chronic viral hepatitis. However, it is still unclear to what extent the underlying cirrhosis may contribute to disease progression. The aim of this study was to compare the long-term outcome of HDV infection with HBV monoinfection in a single-center cohort of both non-cirrhotic and cirrhotic patients. Method: We retrospectively studied 175 patients with chronic hepatitis D (CHD) who were followed for at least 6 months (median of 6.3 (0.6–23.6) years). In addition, we selected 175 patients with HBV monoinfection (CHB) who were matched for gender, age, region of origin, HBeAg status, and bilirubin. Liver-related clinical end points were defined as hepatic decompensation (ascites, encephalopathy, variceal bleeding), liver transplantation, HCC, or liver-related death. Results: Clinical complications developed earlier (4.6 vs. 6.2 years) and more frequently (35.4% vs. 12.6%, p < 0.01) in CHD patients. In a multivariate Cox regression, HDV infection was independently associated with the development of end points (p < 0.01; HR: 3.0; 95% CI 1.4–6.4). However, in cirrhotic patients there were no significant differences between HBV and HDV in the development of end points. Besides, CHB patients with cirrhosis developed more frequently HCC (35.5%) than CHD patients with cirrhosis (18.5%). Conclusion: Our results confirmed that HDV leads to a faster progression to cirrhosis compared to HBV. However, once cirrhosis is present, not HDV but the underlying cirrhosis is the dominate intrinsic risk factor for the development of liver-related end points and for the progression to HCC.
- 3 October 2023
- Published by Springer Nature in Hepatology International
- Vol. 17 (6) , 1359-1367
Open AccessClinical long-term outcome of hepatitis D compared to hepatitis B monoinfection
Background and aims: Hepatitis D virus (HDV) infection causes the most severe form of chronic viral hepatitis. However, it is still unclear to what extent the underlying cirrhosis may contribute to disease progression. The aim of this study was to compare the long-term outcome of HDV infection with HBV monoinfection in a single-center cohort of both non-cirrhotic and cirrhotic patients. Method: We retrospectively studied 175 patients with chronic hepatitis D (CHD) who were followed for at least 6 months (median of 6.3 (0.6–23.6) years). In addition, we selected 175 patients with HBV monoinfection (CHB) who were matched for gender, age, region of origin, HBeAg status, and bilirubin. Liver-related clinical end points were defined as hepatic decompensation (ascites, encephalopathy, variceal bleeding), liver transplantation, HCC, or liver-related death. Results: Clinical complications developed earlier (4.6 vs. 6.2 years) and more frequently (35.4% vs. 12.6%, p < 0.01) in CHD patients. In a multivariate Cox regression, HDV infection was independently associated with the development of end points (p < 0.01; HR: 3.0; 95% CI 1.4–6.4). However, in cirrhotic patients there were no significant differences between HBV and HDV in the development of end points. Besides, CHB patients with cirrhosis developed more frequently HCC (35.5%) than CHD patients with cirrhosis (18.5%). Conclusion: Our results confirmed that HDV leads to a faster progression to cirrhosis compared to HBV. However, once cirrhosis is present, not HDV but the underlying cirrhosis is the dominate intrinsic risk factor for the development of liver-related end points and for the progression to HCC.
- 6 September 2022
- Published by Springer Nature
- p. 343-354
Sekundäre Ursachen der Steatosis hepatis und Steatohepatitis
- 6 September 2022
- Published by Springer Nature
- p. 343-354
Sekundäre Ursachen der Steatosis hepatis und Steatohepatitis
- Open Access
- 1 June 2021
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 12 (6) , e00371
Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis
INTRODUCTION: Metabolic syndrome (MetS) is a major health problem worldwide and the main risk factor for metabolic-associated fatty liver disease (MAFLD). Established treatment options are lifestyle interventions facilitating dietary change and increased physical activity. Here, we tested the effect of a telemonitoring-supported intervention on liver parameter of inflammation and fibrosis in individuals with MetS. METHODS: This was a prospective, randomized, parallel-group, and assessor-blind study performed in workers of the main Volkswagen factory (Wolfsburg, Germany). Volunteers with diagnosed MetS were randomly assigned (1:1) to a 6-month lifestyle intervention focusing on supervised, activity-tracker–guided exercise or to a waiting-list control group. This secondary analysis assessed the effect of the intervention on liver enzymes and MAFLD-related parameters. RESULTS: We screened 543 individuals between October 10, 2017, and February 27, 2018, of whom 314 were randomly assigned to the intervention group (n = 160) or control group (n = 154). Liver transaminases, alkaline phosphatase, and gamma-glutamyl transferase significantly decreased after 6 months in the intervention group compared with the CG. Furthermore, an aspartate aminotransferase-to-platelet ratio index score as a marker for liver fibrosis significantly decreased in the intervention group. These improvements were associated with changes in obesity and exercise capacity. DISCUSSION: A 6-month lifestyle intervention based on exercise training with individualized telemonitoring-based supervision led to improvements of liver inflammation and fibrosis in employees with MetS. Therefore, this intervention shows therapeutic potential for individuals at high risk of MAFLD (ClinicalTrials.gov Identifier: NCT03293264).
- 1 June 2021
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 12 (6) , e00371
Open AccessTelemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis
INTRODUCTION: Metabolic syndrome (MetS) is a major health problem worldwide and the main risk factor for metabolic-associated fatty liver disease (MAFLD). Established treatment options are lifestyle interventions facilitating dietary change and increased physical activity. Here, we tested the effect of a telemonitoring-supported intervention on liver parameter of inflammation and fibrosis in individuals with MetS. METHODS: This was a prospective, randomized, parallel-group, and assessor-blind study performed in workers of the main Volkswagen factory (Wolfsburg, Germany). Volunteers with diagnosed MetS were randomly assigned (1:1) to a 6-month lifestyle intervention focusing on supervised, activity-tracker–guided exercise or to a waiting-list control group. This secondary analysis assessed the effect of the intervention on liver enzymes and MAFLD-related parameters. RESULTS: We screened 543 individuals between October 10, 2017, and February 27, 2018, of whom 314 were randomly assigned to the intervention group (n = 160) or control group (n = 154). Liver transaminases, alkaline phosphatase, and gamma-glutamyl transferase significantly decreased after 6 months in the intervention group compared with the CG. Furthermore, an aspartate aminotransferase-to-platelet ratio index score as a marker for liver fibrosis significantly decreased in the intervention group. These improvements were associated with changes in obesity and exercise capacity. DISCUSSION: A 6-month lifestyle intervention based on exercise training with individualized telemonitoring-based supervision led to improvements of liver inflammation and fibrosis in employees with MetS. Therefore, this intervention shows therapeutic potential for individuals at high risk of MAFLD (ClinicalTrials.gov Identifier: NCT03293264).
- Open Access
- 30 March 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (4) , 353
Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH
Dysregulation of glucose homeostasis plays a major role in the pathogenesis of non-alcoholic steatohepatitis (NASH) as it activates proinflammatory and profibrotic processes. Beneficial effects of antiglycemic treatments such as GLP-1 agonist or SGLT-2 inhibitor on NASH in patients with diabetes have already been investigated. However, their effect on NASH in a non-diabetic setting remains unclear. With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination. Dulaglutide alone and in combination with empagliflozin led to significant weight loss, improved glucose homeostasis and diminished anti-inflammatory and anti-fibrotic pathways. Combination of dulaglutide and empagliflozin further decreased MoMFLy6CHigh and CD4+Foxp3+ T cells. No beneficial effects for treatment with empagliflozin alone could be shown. While no effect of dulaglutide or its combination with empaglifozin on hepatic steatosis was evident, these data demonstrate distinct anti-inflammatory effects of dulaglutide and their combination with empagliflozin in a non-diabetic background, which could have important implications for further treatment of NASH.
- 30 March 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (4) , 353
Open AccessDulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH
Dysregulation of glucose homeostasis plays a major role in the pathogenesis of non-alcoholic steatohepatitis (NASH) as it activates proinflammatory and profibrotic processes. Beneficial effects of antiglycemic treatments such as GLP-1 agonist or SGLT-2 inhibitor on NASH in patients with diabetes have already been investigated. However, their effect on NASH in a non-diabetic setting remains unclear. With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination. Dulaglutide alone and in combination with empagliflozin led to significant weight loss, improved glucose homeostasis and diminished anti-inflammatory and anti-fibrotic pathways. Combination of dulaglutide and empagliflozin further decreased MoMFLy6CHigh and CD4+Foxp3+ T cells. No beneficial effects for treatment with empagliflozin alone could be shown. While no effect of dulaglutide or its combination with empaglifozin on hepatic steatosis was evident, these data demonstrate distinct anti-inflammatory effects of dulaglutide and their combination with empagliflozin in a non-diabetic background, which could have important implications for further treatment of NASH.